Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...

William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

EST Altimmune (ALT) files $400M mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research ...

Altimmune, Inc. announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso, who bring extensive experience in the biopharmaceutical industry.